Probability model of dibunol pharmakinetics.
A mathematical description of the inflow of dibunol from the site of administration and its distribution by organs and tissues in experimental animals and man are examined. Parameters quantitatively characterizing the behavior of the preparation in the organism were obtained. The mechanism of the accumulation of dibunol in the tissues and its subsequent transfer to the blood are described within the framework of the proposed model. The model of the pharmakinetics of dibunol makes possible a calculation of the concentration of the preparation in the tissues depending on the method of administration and special features of the medicinal form. In clinical practice when administered per os microcapsules, which provided maximum absorbability, proved to be the best medicinal form. Satisfactory agreement of the concentrations of the preparation actually observed in a human tumor with those calculated theoretically on the basis of the proposed model was observed.
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D002084:Butylated Hydroxytoluene / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D002214:Capsules; D006801:Humans; D007274:Injections, Intraperitoneal; D007700:Kinetics; D008433:Mathematics; D008954:Models, Biological; D051381:Rats; D013607:Tablets; D013997:Time Factors; D014018:Tissue Distribution; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000378:metabolism
D000970:Antineoplastic Agents; D002214:Capsules; D013607:Tablets; D002084:Butylated Hydroxytoluene